Patents by Inventor Bjarne Due Larsen

Bjarne Due Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210309708
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.
    Type: Application
    Filed: January 21, 2021
    Publication date: October 7, 2021
    Inventors: Bjarne Due LARSEN, Yvette Miata PETERSEN
  • Patent number: 11130793
    Abstract: The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 28, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Lise Giehm, Alistair Vincent Gordon Edwards
  • Publication number: 20210244798
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: April 6, 2020
    Publication date: August 12, 2021
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Patent number: 11001619
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 11, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Patent number: 10905745
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: February 2, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Jonathan Griffin, Lise Giehm, Alistair Vincent Gordon Edwards
  • Publication number: 20200297818
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: April 6, 2020
    Publication date: September 24, 2020
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20200054602
    Abstract: The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 20, 2020
    Applicants: ZEALAND PHARMA A/S, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Bjarne Due LARSEN, Ulrik MOURITZEN, Dongjoon KIM, Sayon ROY
  • Publication number: 20190365865
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20190338009
    Abstract: The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: December 11, 2017
    Publication date: November 7, 2019
    Inventors: Bjarne Due LARSEN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20190330295
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.
    Type: Application
    Filed: January 3, 2019
    Publication date: October 31, 2019
    Inventors: Bjarne Due LARSEN, Yvette Miata PETERSEN
  • Publication number: 20190256569
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: August 22, 2019
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Publication number: 20190142904
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 16, 2019
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Patent number: 10253078
    Abstract: The present invention relates to acylated GIP analogs which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Publication number: 20180362611
    Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.
    Type: Application
    Filed: April 11, 2018
    Publication date: December 20, 2018
    Inventors: Bjarne Due LARSEN, Jens Damsgaard MIKKELSEN, Søren NEVE
  • Patent number: 10092648
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogs disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogs are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: October 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Yvette Miata Petersen
  • Publication number: 20170240609
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 24, 2017
    Applicant: Zealand Pharma A/S
    Inventors: Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
  • Publication number: 20170137487
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.
    Type: Application
    Filed: January 20, 2017
    Publication date: May 18, 2017
    Inventors: Bjarne Due LARSEN, Yvette Miata Petersen
  • Publication number: 20170107267
    Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.
    Type: Application
    Filed: June 15, 2016
    Publication date: April 20, 2017
    Inventors: Bjarne Due LARSEN, Jens Damsgaard MIKKELSEN, Søren NEVE
  • Patent number: 9580487
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogs disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogs are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogs.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: February 28, 2017
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Yvette Miata Petersen
  • Publication number: 20150368314
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.
    Type: Application
    Filed: September 8, 2015
    Publication date: December 24, 2015
    Inventors: Bjarne Due LARSEN, Yvette Miata Petersen